General Information

We are a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Our initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. We have used our precision medicine platform to generate an initial pipeline of four therapeutic programs for the chronic treatment of the two most common forms of heritable cardiomyopathy—hypertrophic cardiomyopathy, or HCM, and dilated cardiomyopathy, or DCM.

Employees: 54
Founded: 2012
Contact Information
Address 333 Allerton Ave. South San Francisco, CA 94080, US
Phone Number (650) 741-0900
Web Address
View Prospectus: MyoKardia
Financial Information
Market Cap $262.4mil
Revenues $13.0 mil (last 12 months)
Net Income $-20.4 mil (last 12 months)
IPO Profile
Symbol MYOK
Exchange NASDAQ
Shares (millions): 5.4
Price range $10.00 - $10.00
Est. $ Volume $54.4 mil
Manager / Joint Managers Credit Suisse/ Cowen and Company
CO-Managers Wedbush PacGrow
Expected To Trade: 10/29/2015
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change